McKesson Corporation (MCK) Cash Flow Statement

A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions.

Total Cash From Operating Activities Chart for McKesson Corporation

McKesson Corporation (MCK) operating cash flow for FY2026 was USD 6.2B, a 1.2% change from FY2025. McKesson Corporation's operating cash flow grew from USD 195.1M in 1995 to USD 6.2B in 2026 (3054.8% over 31 years). Operating cash flow compound annual growth rate: 5-year CAGR of 6.3%, 10-year CAGR of 5.3%, 20-year CAGR of 4.1%.

The most recent 3 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Cash From Operating Activities (US Dollars)

R&D as % of Revenue

Compare with

Key Stats

Market Cap
$101.59B
Implied Share Price
$871.38
Enterprise Value
$101.86B
Revenue (TTM)
$403.43B
EBITDA
$6.88B
Profit Margin
1.18%
Trailing P/E
22.83
Forward P/E
18.76
Price/Book (MRQ)
4.92
Price/Sales (TTM)
0.25
EV/EBITDA
14.19
EV/Revenue
0.25
Dividend Yield
0.00%
Book Value
$-18.10
Free Cash Flow (FY2026)
$5.72B
Free Cash Flow Yield
5.63%

Snapshot as of 7th August 2026 — not point-in-time controlled, may lag the live market by a few days.